Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Institution
- UNIVERSITY OF TX MD ANDERSON CAN CTR, TX
- Principal investigator
- Xiaodong Cheng
- Funding
- $660K
- Duration
- 2020–2030
Moonbase score
Still being scored
Abstract
Summary/Abstract Rapid advancements in identifying readers, writers, and erasers of epigenetic modifications, particularly in DNA and histone marks, have sparked increased interest in understanding their influence on protein-DNA interactions. This interest is driven not only by the essential role of these interactions in gene expression control but also by the emerging potential of DNA-binding transcription factors (TFs) as druggable targets. In mammals, DNA 5-methylcytosine (5mC) serves as a major epigenetic signal that regulates chromatin structure and, consequently, gene expression. Our research has revealed that many DNA-binding TFs are responsive to the CpG methylation status of their binding sites, including unmodified, 5mC, and successively oxidized forms (5-hydroxymethylC, 5-formylC, and 5-carboxyC). Despite these insights, significant challenges persist in unraveling how specific chromatin regions are targeted for methylation, oxidation, and demethylation, understanding the impact of CpG methylation on genome stability, and elucidating the coordinated effects of DNA and histone modifications on TF binding at DNA-regulatory elements to regulate the expression of specific genes.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF TX MD ANDERSON CAN CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of TX MD Anderson Can Ctr37
Preclinical studies of non-nucleoside DNMT3A/3B inhibitors
Taiping Chen · $189K · 2023–2025
- NIH · University of Texas Hlth Sci Ctr HoustonNot yet scored
Epac1 as a novel therapeutic target for diabetic retinopathy
Xiaodong Cheng · $40K · 2025–2026
- NIH · University of Texas Hlth Sci Ctr HoustonNot yet scored
Epac1 as a novel therapeutic target for diabetic retinopathy
Xiaodong Cheng · $506K · 2022–2027